| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Variagenics, Inc. |
| 60 Hampshire Street, Cambridge, MA 02139 * (617) 588-5300 |
| Business Description | The company is a leader in the field of pharmacogenomics. Pharmacogenomics is the study of the correlation between an individual's genetic variability and his or her specific response to a drug. |
| Offering Information Company has | |||
| Trading As | VGNX (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 3/29/00 |
| Domestic Shares Offered | 5,000,000 | Offer Date | 7/20/00 |
| Foreign Shares Offered | 0 | Filing Range | $11.00 - $13.00 |
| Company Shares | 5,000,000 | Offer Price | $14.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.900 |
| Gross Proceeds | $70,000,000 | Selling | $0.580 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 22,310,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| CS First Boston | Lead Manager | (212) 325-2000 |
| Chase H&Q; | Co-manager | (415) 439-3626 |
| SG Cowen | Co-manager | (212) 495-6000 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | ||
| Revenues | 0.000 | 0.000 | 0.000 | 0.000 | 0.399 | - | - |
| Income from Oper. | -1.563 | -2.079 | -4.967 | -8.247 | -15.148 | - | - |
| Net Income | -1.633 | -2.101 | -4.789 | -8.145 | -16.728 | - | - |
| E.P.S | -9.170 | -9.770 | -15.540 | -19.550 | -34.930 | - | - |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -10.40 | - | - | ||||
| Cash Flow - Inv. | -3.10 | - | - | ||||
| Cash Flow - Fin. | 14.59 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 9.40 | Current Assets | 4.52 | Current Ratio | 2.63 |
| Total Liab. | 31.43 | Current Liab. | 1.72 | Debt Ratio | 334.27% |
| Total Equity | -22.03 | Working Cap. | 2.80 | Debt to Equity Ratio | - |
| Cash | 1.83 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for general corporate purposes including research and development and potential acquisitions. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Mintz, Levin, Cohn, Ferris, Glovsky And Popeo |
| Bank's Law Firm | Piper & Marbury |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| The Sprout Group | 27.50 | |
| Atlas Venture | 16.00 | |
| Oxford Bioscience Partners | 13.20 | |
| Forward Ventures | 10.70 | |
| CIBC | 10.70 | |
| Kummell Investments | 8.50 | |
| Note: represents ownership of 5% or more prior to the offering. | ||